Physicians' Academy for Cardiovascular Education

Higher apolipoprotein A1 levels associated with lower risk of ischemic CV outcomes in atrial fibrillation

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

Literature - Pol T, Held C, Westerbergh J, et al. - J Am Heart Assoc. 2018;7:e007444

Main results


In patients with AF treated with oral anticoagulation, higher levels of ApoA1 were independently associated with a lower risk of ischemic CV outcomes, including stroke/SEE and mortality. Higher ApoB levels were associated with higher rates of MI, and an unanticipated higher risk of all-cause mortality in those with lower ApoB levels. These findings suggest that treating dyslipidemia may be important for the improvement of CV outcomes in patients with AF.


Show references

Find this article online at J Am Heart Assoc

Share this page with your colleagues and friends: